Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-FAPI-74 PET/CT Imaging for Fibrotic Disease Activity in Cardiopulmonary Disorders
NCT07613099Phase 3Recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Sep 2026
- Primary completion
- May 2031
- Countries
- 1
01
Overview
A Phase 3 trial of [18F]-FAPI-74 in acute lung injury (ALI), allogeneic stem cell transplantation, cardiovascular disease (CVD), interstitial lung disease (ILD), lung transplantation, sponsored by National Heart, Lung, and Blood Institute. Started Sep 2026; status: recruiting.
02
Drugs
[18F]-FAPI-74
03
Conditions
acute lung injury (ALI)allogeneic stem cell transplantationcardiovascular disease (CVD)interstitial lung disease (ILD)lung transplantation
Beyond the preview
Go deeper on NCT07613099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07613099.